Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526891 | 0.85 | CA2 (1.00) | CA2 | |
| SCHEMBL7520641 | 0.77 | CA2 (0.62) | CA2CA4 | |
| SCHEMBL9682131 | 0.77 | CA2 (0.61) | CA2CA4 | |
| SCHEMBL9683786 | 0.77 | CA2 (0.61) | CA2 | |
| SCHEMBL9682638 | 0.74 | CA2 (0.58) | CA2CA4 | |
| SCHEMBL9683836 | 0.73 | CA2 (0.57) | CA2CA4 | |
| SCHEMBL9682123 | 0.70 | CA2 (1.00) | CA2CA4 | |
| Hydrochloric Acid SCHEMBL9683928 | 0.70 | CA2 (0.98) | CA2CA4 | |
| SCHEMBL9682085 | 0.69 | CA2 (0.61) | CA2CA4 | |
| SCHEMBL9683134 | 0.68 | CA2 (0.51) | CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094981-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO., INC. | 2002-07-18 | — | — | US | claimed |
| EP-0998277-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-10 | — | — | EP | claimed |
| WO-1998053809-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| EP-0479480-A2 | Substituted thieno(2,3-B)(1,4)thiazine-6-sulfonamides as antiglaucoma agents | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | claimed |
| US-5093332-A | SUBSTITUTED THIENO(2,3-B)(1,4)THIAZINE-6-SULFONAMIDES AS ANTIGLAUCOMA AGENTS | MERCK & CO., INC. (US) | 1992-03-03 | — | — | US | claimed |
| US-20020094981-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO., INC. | 2002-07-18 | — | — | US | disclosed |
| EP-0998277-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998053809-A1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0479480-A2 | Substituted thieno(2,3-B)(1,4)thiazine-6-sulfonamides as antiglaucoma agents | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| US-5093332-A | SUBSTITUTED THIENO(2,3-B)(1,4)THIAZINE-6-SULFONAMIDES AS ANTIGLAUCOMA AGENTS | MERCK & CO., INC. (US) | 1992-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094981-A1 | Ophthalmic compositions for treating ocular hypertension | PTGIS, CA2, PTGS1 | CA2 2/4885CA4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.